Tag: clinical trials
Neuroendocrine Tumor Patients and Clinical Trials — Seeking Volunteers for Interviews
A pharmaceutical partner has commissioned a research company to try to understand how clinical trials can be carried out in a way that better suits carcinoid/neuroendocrine tumor patients, their families, and the physicians who treat them. The research…
READ MORE
Clinical Trial for GI Carcinoid Patients Recruiting Through September
Gastrointestinal carcinoid patients who have tumors that either are not suitable for standard treatment or are not responding to standard treatment have the opportunity to enroll in a Phase I/II clinical trial conducted by Tekmira Pharmaceuticals…
READ MORE
Gallium-68 Scan Coming to NOLANETS for Carcinoid and Neuroendocrine Tumor Patients
Dr. Eugene A. Woltering has announced that the Gallium-68 DOTATATE PET/CT scan is going to be available beginning in the summer of 2014 through The New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS) Neuroendocrine Tumor Program at …
READ MORE
A Possible Cure for Neuroendocrine Cancer: Exciting Update!
Back in September 2012 we shared the following: “For $1.6 million (1 million pounds) an oncolytic virus that has the potential to cure neuroendocrine cancer can be named for the donor. At Uppsala University in Sweden researchers are ready to start a …
READ MORE
Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome
Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…
READ MORE
Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment
Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA). LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…
READ MORE
California Carcinoid and Neuroendocrine Tumor Conference Scheduled for January
Carcinoid and neuroendocrine tumor patients and their families are invited to attend the 2012 NET Patient Half Day Conference on Sunday, January 22 in San Francisco, California. The latest developments in NET cancers, including clinical trials, …
READ MORE
Phase II Clinical Trial Recruiting Carcinoid and Related Neuroendocrine Tumor Patients
Participants are being recruited for a Phase II clinical study of capecitabine and temozolomide (CAPTEM) for neuroendocrine cancer patients with progressive, differentiated, metastatic neuroendocrine tumors (NETs). Patients with carcinoid,…
READ MORE
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MORE
Clinical Trials Resources for Carcinoid Cancer & Neuroendocrine Tumor Patients
Carcinoid and neuroendocrine tumor patients can have the latest information about clinical trials delivered directly to their computers – by RSS feed or e-mail. Go to https://clinicaltrials.gov/, in the search field enter the type of trial you are…
READ MORE